RE: Avacta's test20 Apr 2021 12:56
Tsales, This is the subject of their RNS and first paragraph, copied and pasted. It says they plan to begin commercial rollout in Europe in May.
'Completing the technical data set for self-declaration of a CE mark for professional use in early May, followed immediately by commercial launch in Europe
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce positive data from the clinical validation of its AffiDX® SARS-CoV-2 antigen lateral flow test. Data from the clinical study conducted in Europe on 98 positive COVID-19 samples demonstrate excellent performance in identifying the SARS-CoV-2 virus across a broad range of viral loads. These data will now be combined with stability and other performance data from ongoing studies to finalise the technical file for CE marking the AffiDX® SARS-CoV-2 antigen lateral flow test for professional use, allowing the Company to begin commercial roll-out in Europe in May'.